ArticleScientific reports2025
Optogenetic stimulation attenuates central post-stroke pain via BDNF/TrkB signaling pathway modulation in the ascending pain modulation system.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To investigate the role of BDNF/TrkB signaling in Central Post-Stroke Pain (CPSP) and to investigate whether this signaling is related to the analgesic effect of optogenetics. This study was conducted in two parts. First, 40 rats were acquired and randomly divided into four groups: Sham, CPSP, CPSP + ANA-12 (inhibitor of the BDNF/TrkB signaling pathway), and CPSP + 1% DMSO. The Sham group received a saline injection into the Ventral Posterolateral Nucleus of the Thalamus (VPL), whereas the other three groups were injected with type IV collagenase. Additionally, the two groups of CPSP rats were separately injected with ANA-12 or 1% DMSO in the VPL. Second, 50 rats were acquired and randomly divided into five groups: Sham, CPSP, CPSP + NpHR, CPSP + NpHR + BDNF, and CPSP + NpHR + PBS. From day 3 after collagenase injection, rats in the three NpHR groups received yellow laser stimulation at a wavelength of 589 nm six times a day for 12 consecutive days. Subsequently, two groups of stimulated rats were separately injected with BDNF or PBS in the VPL. Optogenetic therapy effectiveness and potential mechanisms were evaluated using pain threshold tests and molecular biology, among other methods. According to the pain threshold test results, optogenetic therapy and ANA-12 injection reversed aberrant CPSP while downregulating BDNF and TrkB. Conversely, exogenous BDNF injection reversed the therapeutic effect of optogenetics on pain. The BDNF/TrkB signaling pathway in the ascending pain modulation system may crucially modulate CPSP in rats. Furthermore, optogenetic therapy could suppress BDNF/TrkB signaling in the ascending pain modulation system, potentially alleviating thalamic hemorrhage-induced Neuropathic Pain (NP).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.